{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:31:08Z","timestamp":1775233868323,"version":"3.50.1"},"reference-count":175,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":2150,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13311-017-0563-6","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T12:37:25Z","timestamp":1502109445000},"page":"999-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Wellness and the Role of Comorbidities in Multiple Sclerosis"],"prefix":"10.1016","volume":"14","author":[{"given":"Brandon P.","family":"Moss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary R.","family":"Rensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie M.","family":"Hersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-017-0563-6_bib1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1212\/WNL.0000000000002469","article-title":"Multiple sclerosis prevalence in the United States commercially insured population","volume":"86","author":"Dilokthornsakul","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-017-0563-6_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-017-0563-6_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2013.778268","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature","volume":"16","author":"Adelman","year":"2013","journal-title":"J Medical Econ"},{"key":"10.1007\/s13311-017-0563-6_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0895-4356(00)00363-2","article-title":"Causes and consequences of comorbidity: a review","volume":"54","author":"Gijsen","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1007\/s13311-017-0563-6_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1212\/01.wnl.0000333252.78173.5f","article-title":"Comorbidity delays diagnosis and increases disability at diagnosis in MS","volume":"72","author":"Marrie","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0404.2011.01526.x","article-title":"Cumulative impact of comorbidity on quality of life in MS","volume":"125","author":"Marrie","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-017-0563-6_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1352458516650512","article-title":"Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course","volume":"23","author":"Conway","year":"2017","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1212\/WNL.0000000000001187","article-title":"Comorbidity increases the risk of hospitalizations in multiple sclerosis","volume":"84","author":"Marrie","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0404.2010.01436.x","article-title":"Association between comorbidity and clinical characteristics of MS","volume":"124","author":"Marrie","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-017-0563-6_bib12","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.162.20.2269","article-title":"Prevalence, expenditures, and complications of multiple chronic conditions in the elderly","volume":"162","author":"Wolff","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1007\/s13311-017-0563-6_bib13","series-title":"Lifestyle Medicine","author":"Rippe","year":"2013"},{"key":"10.1007\/s13311-017-0563-6_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.162.2.133","article-title":"Integrative medicine and systemic outcomes research: issues in the emergence of a new model for primary health care","volume":"162","author":"Bell","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1007\/s13311-017-0563-6_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archinte.162.4.395","article-title":"Integrative medicine: bringing medicine back to its roots","volume":"162","author":"Snyderman","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1007\/s13311-017-0563-6_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI27280","article-title":"Inflamed fat: what starts the fire?","volume":"116","author":"Neels","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-017-0563-6_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2007.01.011","article-title":"A key role of leptin in the control of regulatory T cell proliferation","volume":"26","author":"De Rosa","year":"2007","journal-title":"Immunity"},{"key":"10.1007\/s13311-017-0563-6_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Pasare","year":"2003","journal-title":"Science"},{"key":"10.1007\/s13311-017-0563-6_bib20","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1073\/pnas.0408995102","article-title":"Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells","volume":"102","author":"Matarese","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-017-0563-6_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1352458508096680","article-title":"High frequency of adverse health behaviors in multiple sclerosis","volume":"15","author":"Marrie","year":"2009","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.msard.2012.02.004","article-title":"Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period","volume":"1","author":"Pilutti","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-017-0563-6_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF03405254","article-title":"Validity of self-report screening for overweight and obesity. Evidence from the Canadian Community Health Survey","volume":"99","author":"Elgar","year":"2008","journal-title":"Can J Public Health"},{"key":"10.1007\/s13311-017-0563-6_bib24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/ene.12738","article-title":"Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability","volume":"22","author":"Pinhas-Hamiel","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib25","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/1352458513504252","article-title":"Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis\u2014a systematic review","volume":"19","author":"Wens","year":"2013","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib26","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0003-9993(03)00466-0","article-title":"Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis","volume":"84","author":"Slawta","year":"2003","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-1331.2012.03668.x","article-title":"Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study","volume":"19","author":"Lalmohamed","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1053\/apmr.2002.35663","article-title":"Body composition in ambulatory women with multiple sclerosis","volume":"83","author":"Lambert","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00005768-200206000-00001","article-title":"Coronary heart disease risk between active and inactive women with multiple sclerosis","volume":"34","author":"Slawta","year":"2002","journal-title":"Med Sci Sports Exerc"},{"key":"10.1007\/s13311-017-0563-6_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00365510600727686","article-title":"Effect of resistance training on risk of coronary artery disease in women with multiple sclerosis","volume":"66","author":"White","year":"2006","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1007\/s13311-017-0563-6_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1682\/JRRD.2007.10.0159","article-title":"Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition","volume":"45","author":"Mojtahedi","year":"2008","journal-title":"J Rehabil Res Dev"},{"key":"10.1007\/s13311-017-0563-6_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PHM.0b013e318194f8b5","article-title":"The prevalence of overweight and obesity in veterans with multiple sclerosis","volume":"88","author":"Khurana","year":"2009","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ana.410390405","article-title":"Impact of aerobic training on fitness and quality of life in multiple sclerosis","volume":"39","author":"Petajan","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jocd.2011.04.012","article-title":"Body composition in ambulatory patients with multiple sclerosis","volume":"14","author":"Sioka","year":"2011","journal-title":"J Clin Densitom"},{"key":"10.1007\/s13311-017-0563-6_bib35","doi-asserted-by":"crossref","first-page":"e43675","DOI":"10.1371\/journal.pone.0043675","article-title":"Is metabolic flexibility altered in multiple sclerosis patients?","volume":"7","author":"Mahler","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0563-6_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.09.008","article-title":"Body mass index influence interferon-beta treatment response in multiple sclerosis","volume":"288","author":"Kvistad","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-017-0563-6_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2014.02.038","article-title":"Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study","volume":"340","author":"Tettey","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib38","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458514533162","article-title":"An adverse lipid profile is associated with disability and progression in disability, in people with MS","volume":"20","author":"Tettey","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2377-13-37","article-title":"Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis","volume":"13","author":"Learmonth","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.apmr.2015.09.014","article-title":"Body mass index underestimates adiposity in persons with multiple sclerosis","volume":"97","author":"Pilutti","year":"2016","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1352458514564485","article-title":"A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib42","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp-2012-304740","article-title":"Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event","volume":"84","author":"Weinstock-Guttman","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib43","first-page":"181","article-title":"Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis","volume":"87","author":"Kappus","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib44","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1177\/1352458511414041","article-title":"Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis","volume":"17","author":"Marrie","year":"2011","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/1352458506070768","article-title":"Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis","volume":"12","author":"Kragt","year":"2006","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/WNL.52.1.63","article-title":"Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group","volume":"52","author":"Schwartz","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3988\/jcn.2016.12.3.345","article-title":"Disability progression in multiple sclerosis is affected by the emergence of comorbid arterial hypertension","volume":"12","author":"Dagan","year":"2016","journal-title":"J Clin Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","article-title":"Effect of comorbidity on mortality in multiple sclerosis","volume":"85","author":"Marrie","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib50","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/CPJ.0000000000000269","article-title":"Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS","volume":"6","author":"Salter","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1007\/s13311-017-0563-6_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.65.1.56","article-title":"Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry","volume":"65","author":"Koch-Henriksen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jnnp.2007.127332","article-title":"Survival and cause of death in multiple sclerosis: a prospective population-based study","volume":"79","author":"Hirst","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2190\/PGWT-UXJ0-7UEH-LGRY","article-title":"Major depression and quality of life in individuals with multiple sclerosis","volume":"30","author":"Wang","year":"2000","journal-title":"Int J Psychiatry Med"},{"key":"10.1007\/s13311-017-0563-6_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(02)00312-X","article-title":"Quality of life in patients with multiple sclerosis: the impact of fatigue and depression","volume":"205","author":"Janardhan","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00006199-199711000-00002","article-title":"Correlates of quality of life among persons with multiple sclerosis","volume":"46","author":"Gulick","year":"1997","journal-title":"Nurs Res"},{"key":"10.1007\/s13311-017-0563-6_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0404.1996.tb00512.x","article-title":"Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis","volume":"93","author":"Jonsson","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-017-0563-6_bib58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jad.2014.05.024","article-title":"Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life","volume":"167","author":"Carta","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1007\/s13311-017-0563-6_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.10.003","article-title":"A systematic review of anxiety amongst people with Multiple Sclerosis","volume":"10","author":"Butler","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-017-0563-6_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jns.2013.08.021","article-title":"Improving the quality of mental health care in multiple sclerosis","volume":"335","author":"Minden","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7870\/cjcmh-2005-0011","article-title":"Mental health and mental health service use among people aged 45+ with multiple sclerosis","volume":"24","author":"Garcia","year":"2005","journal-title":"Can J Commun Ment Health"},{"key":"10.1007\/s13311-017-0563-6_bib62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jpsychores.2012.09.011","article-title":"Suicide risk in multiple sclerosis: a systematic review of current literature","volume":"73","author":"Pompili","year":"2012","journal-title":"J Psychosom Res"},{"key":"10.1007\/s13311-017-0563-6_bib63","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/1352458517699873","article-title":"An excessive risk of suicide may no longer be a reality for multiple sclerosis patients","volume":"23","author":"Kalson-Ray","year":"2017","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib64","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1007\/s13311-017-0563-6_bib65","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1352458514564487","article-title":"The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2377-13-16","article-title":"Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance","volume":"13","author":"Marrie","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/WNL.41.5.685","article-title":"Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0022-3999(94)90115-5","article-title":"Depression, cognitive impairment and social stress in multiple sclerosis","volume":"38","author":"Gilchrist","year":"1994","journal-title":"J Psychosom Res"},{"key":"10.1007\/s13311-017-0563-6_bib69","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1037\/0894-4105.13.3.434","article-title":"Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning","volume":"13","author":"Arnett","year":"1999","journal-title":"Neuropsychology"},{"key":"10.1007\/s13311-017-0563-6_bib70","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/archneur.1997.00550170015009","article-title":"Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis","volume":"54","author":"Mohr","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PSY.0b013e3182757b2b","article-title":"Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis","volume":"75","author":"Burns","year":"2013","journal-title":"Psychosom Med"},{"key":"10.1007\/s13311-017-0563-6_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.55.1.55","article-title":"Psychological stress and the subsequent appearance of new brain MRI lesions in MS","volume":"55","author":"Mohr","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.10423","article-title":"New insights into the mechanisms of vitamin D action","volume":"88","author":"Christakos","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1007\/s13311-017-0563-6_bib74","doi-asserted-by":"crossref","first-page":"1689S","DOI":"10.1093\/ajcn\/80.6.1689S","article-title":"Overview of general physiologic features and functions of vitamin D","volume":"80","author":"DeLuca","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1007\/s13311-017-0563-6_bib75","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/me.2002-0363","article-title":"Vitamin D: more than a \u201cbone-a-fide\u201d hormone","volume":"17","author":"Sutton","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1007\/s13311-017-0563-6_bib76","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1210\/jcem-57-6-1308","article-title":"Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation","volume":"57","author":"Bhalla","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s13311-017-0563-6_bib77","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1126\/science.6310748","article-title":"1,25-dihydroxyvitamin D3 receptors in human leukocytes","volume":"221","author":"Provvedini","year":"1983","journal-title":"Science"},{"key":"10.1007\/s13311-017-0563-6_bib78","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"10.1007\/s13311-017-0563-6_bib79","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/abbi.1999.1605","article-title":"Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system","volume":"374","author":"Veldman","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1007\/s13311-017-0563-6_bib80","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1172\/JCI113004","article-title":"Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA","volume":"79","author":"Rigby","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-017-0563-6_bib81","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.4049\/jimmunol.135.4.2279","article-title":"The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis","volume":"135","author":"Rigby","year":"1985","journal-title":"J Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib82","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1126\/science.6427926","article-title":"1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone","volume":"224","author":"Tsoukas","year":"1984","journal-title":"Science"},{"key":"10.1007\/s13311-017-0563-6_bib83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/intimm\/dxr045","article-title":"Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling","volume":"23","author":"Bruce","year":"2011","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib84","doi-asserted-by":"crossref","first-page":"38751","DOI":"10.1074\/jbc.C110.185777","article-title":"Vitamin D suppresses Th17 cytokine production by inducing C\/EBP homologous protein (CHOP) expression","volume":"285","author":"Chang","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-017-0563-6_bib85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/art.25043","article-title":"1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis","volume":"62","author":"Colin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-017-0563-6_bib86","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.4049\/jimmunol.0801543","article-title":"Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response","volume":"182","author":"Tang","year":"2009","journal-title":"J Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.humimm.2009.01.016","article-title":"Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists","volume":"70","author":"Adorini","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib88","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/brain\/awp033","article-title":"Immunomodulatory effects of Vitamin D in multiple sclerosis","volume":"132","author":"Correale","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-017-0563-6_bib89","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1191\/1352458505ms1157oa","article-title":"25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis","volume":"11","author":"Soilu-Hanninen","year":"2005","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib90","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/1352458508094399","article-title":"Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis","volume":"14","author":"Smolders","year":"2008","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00415-006-0315-8","article-title":"Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia","volume":"254","author":"van der Mei","year":"2007","journal-title":"J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","article-title":"Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis","volume":"72","author":"Mowry","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib93","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaneurol.2015.2742","article-title":"Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b","volume":"72","author":"Fitzgerald","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib94","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","article-title":"Vitamin D as an early predictor of multiple sclerosis activity and progression","volume":"71","author":"Ascherio","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib95","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/WNL.0b013e3181e1cec2","article-title":"A phase I\/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis","volume":"74","author":"Burton","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib96","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1177\/1352458511434607","article-title":"Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial","volume":"18","author":"Kampman","year":"2012","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp-2011-301876","article-title":"A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis","volume":"83","author":"Soilu-Hanninen","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000002316","article-title":"Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis","volume":"86","author":"Sotirchos","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib99","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1212\/WNL.0b013e3182343274","article-title":"A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis","volume":"77","author":"Stein","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib100","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/jnnp.2004.056499","article-title":"A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis","volume":"76","author":"Wingerchuk","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2011.04.013","article-title":"Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial","volume":"311","author":"Smolders","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1745-6215-13-15","article-title":"Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial","volume":"13","author":"Dorr","year":"2012","journal-title":"Trials"},{"key":"10.1007\/s13311-017-0563-6_bib103","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cct.2014.10.004","article-title":"The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis","volume":"39","author":"Bhargava","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1007\/s13311-017-0563-6_bib104","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/ijerph8020613","article-title":"Hazardous compounds in tobacco smoke","volume":"8","author":"Talhout","year":"2011","journal-title":"Int J Environ Res Public Health"},{"key":"10.1007\/s13311-017-0563-6_bib105","doi-asserted-by":"crossref","first-page":"986789","DOI":"10.1155\/2013\/986789","article-title":"Th17 cells in immunity and autoimmunity","volume":"2013","author":"Bedoya","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1007\/s13311-017-0563-6_bib106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","article-title":"Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals","volume":"43","author":"Denison","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-017-0563-6_bib107","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06881","article-title":"The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins","volume":"453","author":"Veldhoen","year":"2008","journal-title":"Nature"},{"key":"10.1007\/s13311-017-0563-6_bib108","doi-asserted-by":"crossref","first-page":"e79819","DOI":"10.1371\/journal.pone.0079819","article-title":"Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo","volume":"8","author":"Duarte","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0563-6_bib109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1468-1331.2011.03596.x","article-title":"Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis","volume":"19","author":"D'Hooghe","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib110","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/1352458508093679","article-title":"Smoking is a risk factor for early conversion to clinically definite multiple sclerosis","volume":"14","author":"Di Pauli","year":"2008","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-017-0563-6_bib111","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archneurol.2009.122","article-title":"Smoking and disease progression in multiple sclerosis","volume":"66","author":"Healy","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib112","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/brain\/awh471","article-title":"Cigarette smoking and the progression of multiple sclerosis","volume":"128","author":"Hernan","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-017-0563-6_bib113","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/01.wnl.0000277658.78381.db","article-title":"Cigarette smoking and progression in multiple sclerosis","volume":"69","author":"Koch","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib114","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/brain\/awt139","article-title":"Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study","volume":"136","author":"Manouchehrinia","year":"2013","journal-title":"Brain"},{"key":"10.1007\/s13311-017-0563-6_bib115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2013.04.003","article-title":"Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: a study in IRAN, Guilan","volume":"330","author":"Roudbari","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib116","doi-asserted-by":"crossref","first-page":"e16149","DOI":"10.1371\/journal.pone.0016149","article-title":"Smoking and multiple sclerosis: an updated meta-analysis","volume":"6","author":"Handel","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0563-6_bib117","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jamaneurol.2015.1788","article-title":"Effect of smoking cessation on multiple sclerosis prognosis","volume":"72","author":"Ramanujam","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib118","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jns.2016.09.057","article-title":"Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia","volume":"370","author":"O'Gorman","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib119","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/awh104","article-title":"Trends in survival and cause of death in Danish patients with multiple sclerosis","volume":"127","author":"Bronnum-Hansen","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-017-0563-6_bib120","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s00415-014-7370-3","article-title":"Mortality of patients with multiple sclerosis: a cohort study in UK primary care","volume":"261","author":"Jick","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib121","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/jnnp-2013-307187","article-title":"Tobacco smoking and excess mortality in multiple sclerosis: a cohort study","volume":"85","author":"Manouchehrinia","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib122","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","article-title":"Mortality in patients with multiple sclerosis","volume":"81","author":"Scalfari","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib123","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.apmr.2014.10.014","article-title":"Smoking and physical activity: examining health behaviors and 15-year mortality among individuals with multiple sclerosis","volume":"96","author":"Turner","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib124","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s13311-017-0563-6_bib125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00198-010-1285-3","article-title":"IOF position statement: vitamin D recommendations for older adults","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1007\/s13311-017-0563-6_bib126","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jgs.12631","article-title":"Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences","volume":"62","author":"American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s13311-017-0563-6_bib127","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-017-0563-6_bib128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s001980200023","article-title":"Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study","volume":"13","author":"Chapuy","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1007\/s13311-017-0563-6_bib129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","article-title":"Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial","volume":"326","author":"Trivedi","year":"2003","journal-title":"BMJ"},{"key":"10.1007\/s13311-017-0563-6_bib130","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"10.1007\/s13311-017-0563-6_bib131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s13311-017-0563-6_bib132","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1111\/j.1753-4887.2008.00102.x","article-title":"Vitamin D: criteria for safety and efficacy","volume":"66","author":"Heaney","year":"2008","journal-title":"Nutr Rev"},{"key":"10.1007\/s13311-017-0563-6_bib133","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ajcn\/84.4.694","article-title":"The case against ergocalciferol (vitamin D2) as a vitamin supplement","volume":"84","author":"Houghton","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1007\/s13311-017-0563-6_bib134","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.3390\/nu7075111","article-title":"Factors Affecting 25-Hydroxyvitamin D concentration in response to vitamin D supplementation","volume":"7","author":"Mazahery","year":"2015","journal-title":"Nutrients"},{"key":"10.1007\/s13311-017-0563-6_bib135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ajcn\/73.2.288","article-title":"Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level","volume":"73","author":"Vieth","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1007\/s13311-017-0563-6_bib136","doi-asserted-by":"crossref","first-page":"e15235","DOI":"10.1371\/journal.pone.0015235","article-title":"Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis","volume":"5","author":"Smolders","year":"2010","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0563-6_bib137","first-page":"CD008286","article-title":"Combined pharmacotherapy and behavioural interventions for smoking cessation","volume":"3","author":"Stead","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-017-0563-6_bib138","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-017-0563-6_bib139","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12889-015-2055-0","article-title":"Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Chang","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1007\/s13311-017-0563-6_bib140","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.numecd.2013.08.002","article-title":"Toward a modern Mediterranean diet for the 21st century","volume":"23","author":"Stamler","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1007\/s13311-017-0563-6_bib141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3945\/an.115.011684","article-title":"Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Washington, DC: US Departments of Agriculture and Health and Human Services, 2015","volume":"7","author":"McGuire","year":"2016","journal-title":"Adv Nutr"},{"key":"10.1007\/s13311-017-0563-6_bib142","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10900-014-9913-z","article-title":"Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States","volume":"40","author":"Masullo","year":"2015","journal-title":"J Community Health"},{"key":"10.1007\/s13311-017-0563-6_bib143","series-title":"The Wahls protocol cooking for life : the revolutionary modern Paleo plan to treat all chronic autoimmune conditions","author":"Wahls","year":"2017"},{"key":"10.1007\/s13311-017-0563-6_bib144","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archneur.1970.00480290080009","article-title":"Multiple sclerosis: twenty years on low fat diet","volume":"23","author":"Swank","year":"1970","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcn\/86.1.7","article-title":"Alternate-day fasting and chronic disease prevention: a review of human and animal trials","volume":"86","author":"Varady","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1007\/s13311-017-0563-6_bib146","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.msard.2016.07.001","article-title":"Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial","volume":"9","author":"Yadav","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-017-0563-6_bib147","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/jnnp-2014-307928","article-title":"Sodium intake is associated with increased disease activity in multiple sclerosis","volume":"86","author":"Farez","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib148","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000197108","article-title":"Short-term effects of prolonged fasting on multiple sclerosis","volume":"61","author":"Saadatnia","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib149","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/acm.2013.0188","article-title":"A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue","volume":"20","author":"Bisht","year":"2014","journal-title":"J Altern Complement Med"},{"key":"10.1007\/s13311-017-0563-6_bib150","unstructured":"Dietary Guidelines for Americans 2015\u20132020. Available at: http:\/\/health.gov\/dietaryguidelines\/2015\/guidelines\/. Accessed July 31, 2017."},{"key":"10.1007\/s13311-017-0563-6_bib151","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11910-015-0585-6","article-title":"Benefits of exercise training in multiple sclerosis","volume":"15","author":"Motl","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-017-0563-6_bib152","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2014.05.016","article-title":"The safety of exercise training in multiple sclerosis: a systematic review","volume":"343","author":"Pilutti","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-017-0563-6_bib153","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.apmr.2015.02.011","article-title":"Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis","volume":"96","author":"Pearson","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib154","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s13311-017-0563-6_bib155","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.apmr.2015.05.018","article-title":"Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis","volume":"96","author":"Gunn","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-017-0563-6_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009956.pub2","article-title":"Exercise therapy for fatigue in multiple sclerosis","author":"Heine","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-017-0563-6_bib157","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11065-016-9324-2","article-title":"Systematic, Evidence-based review of exercise, physical activity, and physical fitness effects on cognition in persons with multiple sclerosis","volume":"26","author":"Sandroff","year":"2016","journal-title":"Neuropsychol Rev"},{"key":"10.1007\/s13311-017-0563-6_bib158","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00234-016-1767-x","article-title":"Exercise training effects on memory and hippocampal viscoelasticity in multiple sclerosis: a novel application of magnetic resonance elastography","volume":"59","author":"Sandroff","year":"2017","journal-title":"Neuroradiology"},{"key":"10.1007\/s13311-017-0563-6_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009974.pub2","article-title":"Non pharmacological interventions for spasticity in multiple sclerosis","author":"Amatya","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-017-0563-6_bib160","doi-asserted-by":"crossref","first-page":"e112414","DOI":"10.1371\/journal.pone.0112414","article-title":"Yoga for multiple sclerosis: a systematic review and meta-analysis","volume":"9","author":"Cramer","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1007\/s13311-017-0563-6_bib161","unstructured":"Multiple Sclerosis: NCHPAD - Building Inclusive Communities. www.nchpad.org\/70\/527\/Multiple\u223cSclerosis. Accessed On: 8\/4\/17"},{"key":"10.1007\/s13311-017-0563-6_bib162","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.msard.2015.10.004","article-title":"Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis","volume":"5","author":"Fiest","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-017-0563-6_bib163","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.genhosppsych.2007.08.002","article-title":"Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis","volume":"30","author":"Ehde","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib164","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1037\/0022-006X.69.6.942","article-title":"Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis","volume":"69","author":"Mohr","year":"2001","journal-title":"J Consult Clin Psychol"},{"key":"10.1007\/s13311-017-0563-6_bib165","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1176\/ajp.147.11.1493","article-title":"Antidepressant pharmacotherapy of depression associated with multiple sclerosis","volume":"147","author":"Schiffer","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib166","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/WNF.0b013e3182996400","article-title":"Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study","volume":"36","author":"Solaro","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-017-0563-6_bib167","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/070674379203700222","article-title":"The effect of fluoxetine in depression associated with multiple sclerosis","volume":"37","author":"Shafey","year":"1992","journal-title":"Can J Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib168","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/01616412.1995.11740355","article-title":"Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale","volume":"17","author":"Scott","year":"1995","journal-title":"Neurol Res"},{"key":"10.1007\/s13311-017-0563-6_bib169","first-page":"86","article-title":"A double-blind trial with an antidepressant drug, imipramine, in multiple sclerosis","volume":"43","author":"Dean","year":"1969","journal-title":"S Afr Med J"},{"key":"10.1007\/s13311-017-0563-6_bib170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/09540261003589323","article-title":"The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour","volume":"22","author":"Paparrigopoulos","year":"2010","journal-title":"Int Rev Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib171","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/WNL.0b013e3182616ff9","article-title":"A randomized trial of stress management for the prevention of new brain lesions in MS","volume":"79","author":"Mohr","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-017-0563-6_bib172","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2377-14-15","article-title":"Mindfulness based interventions in multiple sclerosis--a systematic review","volume":"14","author":"Simpson","year":"2014","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-017-0563-6_bib173","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0163-8343(00)00100-6","article-title":"Mindfulness of movement as a coping strategy in multiple sclerosis. A pilot study","volume":"22","author":"Mills","year":"2000","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1007\/s13311-017-0563-6_bib174","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7224\/1537-2073-13.4.163","article-title":"Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study","volume":"13","author":"Tavee","year":"2011","journal-title":"Int J MS Care"},{"key":"10.1007\/s13311-017-0563-6_bib175","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1212\/WNL.0b013e3181f4d80d","article-title":"MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial","volume":"75","author":"Grossman","year":"2010","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0563-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0563-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0563-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:35Z","timestamp":1761807455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":175,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1878747923014204"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0563-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wellness and the Role of Comorbidities in Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0563-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}